SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011;117:50195032.
  • 2
    Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp 157166.
  • 3
    Craig FE. Flow cytometric evaluation of B-cell lymphoid neoplasms. Clin Lab Med 2007;27:487512, vi.
  • 4
    Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:39413967.
  • 5
    Stetler-Stevenson M. Flow cytometry in lymphoma diagnosis and prognosis: Useful? Best Pract Res Clin Haematol 2003;16:583597.
  • 6
    Kroft SH. Uncovering clinically relevant phenotypic variations in malignancies: CD23 in mantle cell lymphoma. Am J Clin Pathol 2008;130:159161.
  • 7
    Sanchez ML, Almeida J, Vidriales B, Lopez-Berges MC, Garcia-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: Basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002;16:14601469.
  • 8
    Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M, Couris CM, Thieblemont C, Morel D, Coiffier B, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: A clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica;95:604612.
  • 9
    Asplund SL, McKenna RW, Doolittle JE, Kroft SH. CD5-positive B-cell neoplasms of indeterminate immunophenotype: A clinicopathologic analysis of 26 cases. Appl Immunohistochem Mol Morphol 2005;13:311317.
  • 10
    Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, et al. CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity. Cytometry Part B Clin Cytom 2010;78B Suppl 1:S3541.
  • 11
    Menendez P, Vargas A, Bueno C, Barrena S, Almeida J, De Santiago M, Lopez A, Roa S, San Miguel JF, Orfao A. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 2004;18:491498.
  • 12
    Del Giudice I, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, A'Hern R, Delgado J, Bazerbashi MB, Catovsky D. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004;89:303308.
  • 13
    Stetler-Stevenson M, Tembhare PR. Diagnosis of hairy cell leukemia by flow cytometry. Leuk Lymphoma 2011;52 Suppl 2:113.
  • 14
    Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol 2010;134:726733.
  • 15
    El Desoukey NA, Afify RA, Amin DG, Mohammed RF. CD200 expression in B-cell chronic lymphoproliferative disorders. J Investig Med 2012;60:5661.
  • 16
    Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, Lorsbach RB. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 2012;137:93100.
  • 17
    Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, Conticello C, Villari L, Di Raimondo F. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009;33:12121216.
  • 18
    van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:19081975.
  • 19
    Demurtas A, Stacchini A, Aliberti S, Chiusa L, Chiarle R, Novero D. Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases. Cytometry Part B Clin Cytom 2013;84B:8295.
  • 20
    Brunetti L, Di Noto R, Abate G, Gorrese M, Gravetti A, Raia M, Scalia G, Pascariello C, Camera A, Del Vecchio L. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009;145:665667.
  • 21
    Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378382.
  • 22
    Stewart CC, Stewart SJ. Immunophenotyping. Curr Protoc Cytom 2001;Chapter 6:Unit 6 2.
  • 23
    Costa ES, Pedreira CE, Barrena S, Lecrevisse Q, Flores J, Quijano S, Almeida J, del Carmen Garcia-Macias M, Bottcher S, Van Dongen JJ, et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: A step forward in the standardization of clinical immunophenotyping. Leukemia 2010;24:19271933.
  • 24
    Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2010;35:7683.
  • 25
    van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lecrevisse Q, Lucio P, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:19081975.
  • 26
    Olteanu H, Harrington AM, Kroft SH. Immunophenotypic stability of CD200 expression in plasma cell myeloma. Am J Clin Pathol 2012;137:10131014.
  • 27
    Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol 2011;153:408411.
  • 28
    Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:41944197.
  • 29
    Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, Darley RL. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566568.
  • 30
    Pedreira CE, Costa ES, Barrena S, Lecrevisse Q, Almeida J, van Dongen JJ, Orfao A. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry Part A 2008;73A:834846.
  • 31
    Pedreira CE, Costa ES, Arroyo ME, Almeida J, Orfao A. A multidimensional classification approach for the automated analysis of flow cytometry data. IEEE Trans Biomed Eng 2008;55:11551162.
  • 32
    Pedreira CE, Costa ES, Almeida J, Fernandez C, Quijano S, Flores J, Barrena S, Lecrevisse Q, Van Dongen JJ, Orfao A. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry Part A 2008;73A:11411150.
  • 33
    Costa ES, Arroyo ME, Pedreira CE, Garcia-Marcos MA, Tabernero MD, Almeida J, Orfao A. A new automated flow cytometry data analysis approach for the diagnostic screening of neoplastic B-cell disorders in peripheral blood samples with absolute lymphocytosis. Leukemia 2006;20:12211230.
  • 34
    Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: Clinicopathologic features of 18 cases. Am J Clin Pathol 2003;120:760766.
  • 35
    Kelemen K, Peterson LC, Helenowski I, Goolsby CL, Jovanovic B, Miyata S, Aranha O, Rosen ST, Winter JN, Nelson BP, et al. CD23+ mantle cell lymphoma: A clinical pathologic entity associated with superior outcome compared with CD23-disease. Am J Clin Pathol 2008;130:166177.
  • 36
    Gao J, Peterson L, Nelson B, Goolsby C, Chen YH. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol 2009;132:699706.
  • 37
    Kraus TS, Sillings CN, Saxe DF, Li S, Jaye DL. The role of CD11c expression in the diagnosis of mantle cell lymphoma. Am J Clin Pathol 2010;134:271277.
  • 38
    Marotta G, Raspadori D, Sestigiani C, Scalia G, Bigazzi C, Lauria F. Expression of the CD11c antigen in B-cell chronic lymphoproliferative disorders. Leuk Lymphoma 2000;37:145149.
  • 39
    Kost CB, Holden JT, Mann KP. Marginal zone B-cell lymphoma: A retrospective immunophenotypic analysis. Cytometry Part B Clin Cytom 2008;74B:282286.
  • 40
    Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B- and T-cell subtype: A state-of-the-art paper. Eur J Haematol 2008;80:469476.
  • 41
    Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 2001;115:571581.
  • 42
    Ruchlemer R, Parry-Jones N, Brito-Babapulle V, Attolico I, Wotherspoon AC, Matutes E, Catovsky D. B-prolymphocytic leukaemia with t(11;14) revisited: A splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol 2004;125:330336.
  • 43
    Wong KF, So CC, Chan JK. Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol 2002;117:246251.
  • 44
    Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:2638.